RecipharmCobra Biologics Receives Patent for Antibiotic-Free Plasmid Maintenance System
RecipharmCobra Biologics Receives Patent for Antibiotic-Free Plasmid Maintenance System
RecipharmCobra Biologics (Keele, UK) has been granted European and US patents for oriSELECT, its antibody-free plasmid maintenance system.
Classically, genes of interest are inserted into plasmids with antibiotic resistance genes, and then inserted into E. coli with antibiotics present. Only E. coli cells that contain both the inserted genes and the antibiotic resistance genes will survive to produce plasmids or proteins. OriSELECT enables the production of plasmids or proteins in E. coli without the requirement for antibiotics in the medium or for plasmid selection and maintenance. This avoids some of the problems associated with the conventional selection method, including loss of the plasmid from the cell during cell division (which can reduce product yield), product contamination with antibiotics, and the potential transfer risk of antibiotic resistance genes to pathogens.
Although there are other antibiotic-free plasmid maintenance systems available, oriSELECT requires no selectable marker genes on the plasmid, thereby allowing smaller plasmids to be produced, and reducing the metabolic burden associated with selectable marker gene expression. The key to oriSELECT is that the pMB1 plasmid origin of replication, which is essential for plasmid replication, acts as the selectable marker. This means that no further modifications are needed to the plasmid, and existing plasmids can have their antibiotic resistance genes excised for use in the oriSELECT system.
The pMB1 origin of replication produces two RNA molecules, which regulate plasmid replication. The oriSELECT E. coli strain is modified such that an essential gene is controlled by one of these RNA molecules, and is switched off in the absence of a plasmid, preventing cell growth. Insertion of a plasmid enables the essential gene to be expressed, thus permitting cell growth and plasmid maintenance.
The Future of Cleanroom Construction: How Hybrid Solutions are Changing the Game
May 14th 2025Imagine a world where cleanroom facilities—essential for pharmaceutical manufacturing, biotechnology, and high-tech industries—are built with unparalleled speed, precision, and efficiency. That world is here, thanks to the hybrid construction approach. By blending traditional stick-built methods with modular and prefabricated solutions, companies are overcoming the limitations of conventional construction while ensuring compliance with stringent industry regulations. In this interview, we explore how hybrid cleanroom construction is transforming the industry, offering faster project timelines, improved quality control, and significant cost advantages. Join us as we delve into this game-changing approach with industry experts who are leading the charge in revolutionizing cleanroom infrastructure.
Mastering Antibody-Drug Conjugates
December 19th 2024In this episode, we explore BIOVECTRA’s capabilities in antibody-drug conjugate (ADC) manufacturing, from complex conjugation chemistry to synthesis of highly potent payloads. We’ll also showcase how BIOVECTRA’s extensive experience in complex chemistries and specialized small molecule manufacturing gives them a unique perspective, strengthening their approach to ADC production and ensuring clients receive custom solutions across all project stages.
